多発性骨髄腫における従来型化学療法薬の世界市場:企業別、地域別、種類別、用途別、市場予測(~2024)

GlobalInfoResearchが発行した調査報告書(GIR9076038)
◆英語タイトル:Global Traditional Chemotherapy Drugs for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024
◆商品コード:GIR9076038
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2019年7月(※2024年版があります。お問い合わせください。)
◆ページ数:138
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医薬品・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは、多発性骨髄腫における従来型化学療法薬の世界市場について調べ、まとめました。種類別セグメントは、メルファラン、ビンクリスチン、シクロホスファミド、エトポシド、ドキソルビシン、リポソームドキソルビシン、ベンダムスチン、その他等、用途別セグメントは、コンシューマー事業、エンタープライズ事業、オペレーター事業等に区分しました。多発性骨髄腫における従来型化学療法薬の世界市場概観、企業動向、企業別多発性骨髄腫における従来型化学療法薬シェア、市場規模推移、市場規模予測(2019年-2024年)、主要地域分析(北米、ヨーロッパ、アジア等)、主要国分析(日本、中国、アメリカ等)データなどの情報が含まれています。
・多発性骨髄腫における従来型化学療法薬の市場概観
・多発性骨髄腫における従来型化学療法薬の企業概要(事業概要、製品種類、販売量、価格、売上、市場シェア等)
・多発性骨髄腫における従来型化学療法薬の企業別販売動向、市場シェア、市場集中度、競争動向
・多発性骨髄腫における従来型化学療法薬の世界市場規模
・多発性骨髄腫における従来型化学療法薬の北米市場分析(アメリカ、カナダ、メキシコ等)
・多発性骨髄腫における従来型化学療法薬のアメリカ市場規模推移
・多発性骨髄腫における従来型化学療法薬のカナダ市場規模推移
・多発性骨髄腫における従来型化学療法薬のメキシコ市場規模推移
・多発性骨髄腫における従来型化学療法薬のヨーロッパ市場分析(ドイツ、イギリス、ロシア、フランス、イタリア等)
・多発性骨髄腫における従来型化学療法薬のドイツ市場規模推移
・多発性骨髄腫における従来型化学療法薬のイギリス市場規模推移
・多発性骨髄腫における従来型化学療法薬のロシア市場規模推移
・多発性骨髄腫における従来型化学療法薬のアジア太平洋市場分析(日本、中国、韓国、インド、東南アジア等)
・多発性骨髄腫における従来型化学療法薬の日本市場規模推移
・多発性骨髄腫における従来型化学療法薬の中国市場規模推移
・多発性骨髄腫における従来型化学療法薬の韓国市場規模推移
・多発性骨髄腫における従来型化学療法薬のインド市場規模推移
・多発性骨髄腫における従来型化学療法薬の東南アジア市場規模推移
・多発性骨髄腫における従来型化学療法薬の南米市場分析(ブラジル、アルゼンチン等)
・多発性骨髄腫における従来型化学療法薬の中東・アフリカ市場分析(サウジアラビア、UAE、南アフリカ等)
・多発性骨髄腫における従来型化学療法薬の種類別分析/販売量、売上、市場シェア(メルファラン、ビンクリスチン、シクロホスファミド、エトポシド、ドキソルビシン、リポソームドキソルビシン、ベンダムスチン、その他)
・多発性骨髄腫における従来型化学療法薬の用途別分析/市場規模(コンシューマー事業、エンタープライズ事業、オペレーター事業)
・多発性骨髄腫における従来型化学療法薬の市場予測2019年-2024年(地域別予測、種類別予測、用途別予測)
・多発性骨髄腫における従来型化学療法薬の販売チャネル・代理店・貿易業者・ディーラー分析
【レポートの概要】

Scope of the Report:
The global Traditional Chemotherapy Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Traditional Chemotherapy Drugs for Multiple Myeloma.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Traditional Chemotherapy Drugs for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Traditional Chemotherapy Drugs for Multiple Myeloma market by product type and applications/end industries.

Market Segment by Companies, this report covers
GlaxoSmithKline
Celon Laboratories
Natco Pharma
Emcure Pharmaceuticals
GLS Pharma
Talon Therapeutics
Shenzhen Main Luck Pharmaceuticals
Cipla
ACTIZA
Hospira
Baxter
Roxane
Sanofi
CSC Pharmaceuticals
LGM Pharma
Pfizer
Merck
Allergan
Teva
Mylan
Qilu Pharmaceutical
Sun Pharmaceuticals
Cadila Pharmaceuticals
Simcere Pharmaceutical
Get Well Pharmaceutical

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Melphalan
Vincristine
Cyclophosphamide
Etoposide
Doxorubicin
Liposome Doxorubicin
Bendamustine
Other

Market Segment by Applications, can be divided into
Hospital
Clinic
Drug Center
Other

【レポートの目次】

Table of Contents

1 Traditional Chemotherapy Drugs for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of Traditional Chemotherapy Drugs for Multiple Myeloma
1.2 Classification of Traditional Chemotherapy Drugs for Multiple Myeloma by Types
1.2.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Comparison by Types (2019-2024)
1.2.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
1.2.3 Melphalan
1.2.4 Vincristine
1.2.5 Cyclophosphamide
1.2.6 Etoposide
1.2.7 Doxorubicin
1.2.8 Liposome Doxorubicin
1.2.9 Bendamustine
1.2.10 Other
1.3 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market by Application
1.3.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market by Regions
1.4.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Traditional Chemotherapy Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.5 Global Market Size of Traditional Chemotherapy Drugs for Multiple Myeloma (2014-2024)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.2 Celon Laboratories
2.2.1 Business Overview
2.2.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celon Laboratories Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.4 Emcure Pharmaceuticals
2.4.1 Business Overview
2.4.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Emcure Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.5 GLS Pharma
2.5.1 Business Overview
2.5.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GLS Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.6 Talon Therapeutics
2.6.1 Business Overview
2.6.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Talon Therapeutics Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.7 Shenzhen Main Luck Pharmaceuticals
2.7.1 Business Overview
2.7.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Shenzhen Main Luck Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.8 Cipla
2.8.1 Business Overview
2.8.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Cipla Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.9 ACTIZA
2.9.1 Business Overview
2.9.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 ACTIZA Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.10 Hospira
2.10.1 Business Overview
2.10.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Hospira Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.11 Baxter
2.11.1 Business Overview
2.11.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Baxter Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.12 Roxane
2.12.1 Business Overview
2.12.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Roxane Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.13 Sanofi
2.13.1 Business Overview
2.13.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Sanofi Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.14 CSC Pharmaceuticals
2.14.1 Business Overview
2.14.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 CSC Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.15 LGM Pharma
2.15.1 Business Overview
2.15.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 LGM Pharma Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.16 Pfizer
2.16.1 Business Overview
2.16.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Pfizer Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.17 Merck
2.17.1 Business Overview
2.17.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Merck Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.18 Allergan
2.18.1 Business Overview
2.18.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Allergan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.19 Teva
2.19.1 Business Overview
2.19.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Teva Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.20 Mylan
2.20.1 Business Overview
2.20.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Mylan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.21 Qilu Pharmaceutical
2.21.1 Business Overview
2.2.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Qilu Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.22 Sun Pharmaceuticals
2.22.1 Business Overview
2.22.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Sun Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.23 Cadila Pharmaceuticals
2.23.1 Business Overview
2.23.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Cadila Pharmaceuticals Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.24 Simcere Pharmaceutical
2.24.1 Business Overview
2.24.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Simcere Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.25 Get Well Pharmaceutical
2.25.1 Business Overview
2.25.2 Traditional Chemotherapy Drugs for Multiple Myeloma Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Get Well Pharmaceutical Traditional Chemotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
3 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Competition, by Players
3.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Traditional Chemotherapy Drugs for Multiple Myeloma Players Market Share
3.2.2 Top 10 Traditional Chemotherapy Drugs for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size by Regions
4.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.3 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.5 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
5.1 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
5.2 USA Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.3 Canada Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.4 Mexico Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
6.1 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
6.2 Germany Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.3 UK Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.4 France Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.5 Russia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.6 Italy Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
7.2 China Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.3 Japan Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.4 Korea Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.5 India Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries
8.1 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
8.2 Brazil Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.3 Argentina Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.4 Colombia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Traditional Chemotherapy Drugs for Multiple Myeloma by Countries
9.1 Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
9.2 Saudi Arabia Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.3 UAE Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.4 Egypt Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.5 Nigeria Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.6 South Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
10 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Segment by Type
10.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue and Market Share by Type (2014-2019)
10.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Forecast by Type (2019-2024)
10.3 Melphalan Revenue Growth Rate (2014-2024)
10.4 Vincristine Revenue Growth Rate (2014-2024)
10.5 Cyclophosphamide Revenue Growth Rate (2014-2024)
10.6 Etoposide Revenue Growth Rate (2014-2024)
10.7 Doxorubicin Revenue Growth Rate (2014-2024)
10.8 Liposome Doxorubicin Revenue Growth Rate (2014-2024)
10.9 Bendamustine Revenue Growth Rate (2014-2024)
10.10 Other Revenue Growth Rate (2014-2024)
11 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Segment by Application
11.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Share by Application (2014-2019)
11.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Clinic Revenue Growth (2014-2019)
11.5 Drug Center Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.1 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Forecast by Regions (2019-2024)
12.3 North America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.4 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.6 South America Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Traditional Chemotherapy Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 多発性骨髄腫における従来型化学療法薬の世界市場:企業別、地域別、種類別、用途別、市場予測(~2024)(Global Traditional Chemotherapy Drugs for Multiple Myeloma Market 2019 by Company, Regions, Type and Application, Forecast to 2024)]についてメールでお問い合わせはこちらでお願いします。